Company Overview
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 57.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Dec 2025 Revenue of $35.58M (+370.2% YoY); net profit $-17.89M.
- Trailing 12 Months Year-on-year growth — revenue +46.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 57.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 57.93% |
| 1 Year: | 46.10% |
Stock Price Performance
| 1 Year: | -2.30% |
| 6 Months: | -25.44% |
| 3 Months: | -23.04% |
| 1 Month: | -9.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.80 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 57.9% over 5 years.
CONS
- Trading 39.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VRCA Verrica Pharmaceuticals Inc. | 5.51 | -5.01 | $94.66M | 0.00% | -38.90% | -72.29% | 57.93% | - |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.00M | 0 | 0 | 431.00K | 214.00K | 8.32M | 37.00K | 182.00K | 2.92M | 3.83M | 5.18M | -1.78M | - | 3.44M | 12.70M | 14.34M | 5.09M | 5.02M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 437.00K | 494.00K | 1.11M | 1.40M | 889.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00M | 12.21M | 13.23M | 3.69M | 4.13M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.13M | 10.70M | 11.61M | 10.64M | 13.85M |
| Operating Income | -570.00K | -1.09M | -1.36M | -1.43M | -1.89M | -5.47M | -6.33M | -8.19M | -8.03M | -7.52M | -6.54M | -7.99M | -9.88M | -8.63M | -9.64M | 60.00K | -10.73M | -11.77M | -7.41M | -9.12M | 1.45M | -7.09M | -11.62M | -23.92M | -18.60M | -15.21M | -20.70M | - | -8.13M | 1.51M | 1.63M | -6.95M | -9.71M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.33M | 2.53M | 2.00M | -6.57M | -9.33M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.20M | 2.13M | 2.09M | 1.31M | 160.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.74M | 204.00K | -274.00K | -8.07M | -9.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -570.00K | -1.09M | -1.36M | -1.44M | -1.85M | -5.32M | -5.91M | -7.58M | -7.48M | -7.00M | -6.09M | -7.64M | -9.82M | -9.41M | -10.49M | -936.00K | -11.78M | -12.83M | -8.47M | -10.17M | 83.00K | -6.59M | -10.99M | -24.80M | -20.33M | -17.19M | -22.86M | - | -9.74M | 204.00K | -274.00K | -8.07M | -9.68M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.43 | -0.47 | -0.31 | -0.37 | 0.00 | -0.15 | -0.24 | -0.54 | -0.44 | -3.70 | -4.88 | - | -1.00 | 0.02 | -0.03 | -0.57 | -0.45 |
| R&D Expense | 515.00K | 977.00K | 1.12M | 1.12M | 927.00K | 3.52M | 3.47M | 4.92M | 4.49M | 3.93M | 3.05M | 3.97M | 4.89M | 3.52M | 4.99M | 5.36M | 3.45M | 3.76M | 2.44M | 3.94M | 2.78M | 2.74M | 5.72M | 6.51M | 4.95M | 3.32M | 2.40M | - | 2.28M | 1.85M | 2.21M | - | 3.86M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 9.03M | 5.12M | 7.57M | 35.58M |
| Cost of Revenue | - | - | - | - | - | 725.00K | 746.00K | 2.74M | 3.44M |
| Gross Profit | - | - | - | - | - | 8.31M | 4.38M | 4.83M | 32.14M |
| Operating Expenses | - | - | - | - | - | 29.60M | 67.60M | 70.66M | 44.08M |
| Operating Income | -4.46M | -21.88M | -30.08M | -40.18M | - | -21.30M | -63.22M | -65.84M | -11.94M |
| EBITDA | - | - | - | - | - | -21.60M | -62.20M | -65.90M | -9.36M |
| Interest Expense | - | - | - | - | - | 2.17M | 3.96M | 9.41M | 7.74M |
| Pretax Income | - | - | - | - | - | -24.49M | -67.00M | -76.58M | -17.89M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -4.46M | -20.65M | -28.21M | -42.69M | - | -24.49M | -67.00M | -76.58M | -17.89M |
| Diluted EPS | - | - | - | - | - | -7.20 | -14.80 | -14.80 | -1.68 |
| R&D Expense | 3.73M | 12.83M | 15.44M | 15.67M | 15.93M | 12.20M | 20.30M | 11.84M | 8.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Jul 2022 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 9.08M | 91.91M | 68.42M | 74.15M | - | - | 44.72M | 81.60M | 54.13M | 47.13M |
| Current Assets | - | - | - | - | - | - | - | 39.12M | 77.53M | 51.18M | 42.54M |
| Cash & Equivalents | 527.00K | 8.66M | 10.27M | 9.24M | 10.69M | - | 40.00M | 34.27M | 69.55M | 46.33M | 30.15M |
| Inventory | - | - | - | - | - | - | - | 0 | 1.02M | 2.46M | 2.24M |
| Receivables | - | - | - | - | - | - | - | 388.00K | 4.25M | 48.00K | 5.26M |
| Total Liabilities | - | 616.00K | 2.48M | 3.41M | 41.17M | - | - | 4.69M | 61.83M | 63.99M | 22.39M |
| Current Liabilities | - | 616.00K | 2.48M | 3.35M | 39.48M | - | - | 3.46M | 17.02M | 29.01M | 16.44M |
| Long Term Debt | - | - | - | - | - | - | - | - | 42.87M | 30.98M | - |
| Total Debt | - | - | - | - | - | - | - | 1.53M | 45.51M | 45.94M | 1.63M |
| Total Equity | -2.66M | -7.04M | 89.43M | 65.02M | 32.99M | - | - | 40.03M | 19.76M | -9.86M | 24.74M |
| Shares Outstanding | - | - | - | - | - | - | - | 4.12M | 4.25M | 9.19M | 17.19M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.58M | -17.87M | -27.41M | -30.21M | - | -18.65M | -38.58M | -60.93M | -17.63M |
| Investing Cash Flow | - | -79.89M | 25.95M | -3.58M | - | 54.04M | -362.00K | -19.00K | 0 |
| Financing Cash Flow | 12.72M | 99.38M | 423.00K | 35.23M | - | -16.87M | 74.21M | 37.73M | 1.45M |
| Capital Expenditure | - | -774.00K | -682.00K | -1.47M | -883.00K | -302.00K | -362.00K | -27.00K | - |
| Free Cash Flow | - | -18.65M | -28.09M | -31.68M | - | -18.95M | -38.94M | -60.95M | -17.63M |
| Net Change in Cash | - | - | - | - | - | 18.52M | 35.27M | -23.22M | -16.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 92.0% | 85.4% | 63.8% | 90.3% |
| Operating Margin % | - | - | - | - | - | -235.8% | -1,233.8% | -870.2% | -33.6% |
| Net Margin % | - | - | - | - | - | -271.1% | -1,307.5% | -1,012.1% | -50.3% |
| ROE % | 63.3% | -23.1% | -43.4% | -129.4% | - | -61.2% | -339.0% | 776.7% | -72.3% |
| ROCE % | -52.6% | -24.5% | -46.2% | -115.9% | - | -51.6% | -97.9% | -262.1% | -38.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Caligan Partners, LP | 5.38% | 923.91K | $4.85M |
| 2 | Affinity Asset Advisors, Llc | 4.12% | 707.34K | $3.71M |
| 3 | Cannell Capital LLC | 3.99% | 685.12K | $3.60M |
| 4 | Armistice Capital, LLC | 3.02% | 518.18K | $2.72M |
| 5 | Velan Capital Investment Management LP | 2.75% | 471.56K | $2.48M |
| 6 | Boothbay Fund Management, LLC | 1.63% | 280.73K | $1.47M |
| 7 | Vanguard Capital Management LLC | 1.10% | 188.76K | $990.98K |
| 8 | DAFNA Capital Management, LLC | 0.89% | 153.71K | $806.99K |
| 9 | Marshall Wace LLP | 0.82% | 140.50K | $737.61K |
| 10 | Geode Capital Management, LLC | 0.81% | 138.92K | $729.31K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VRCA
Verrica Sets Aug. 6 Webcast to Discuss Second-Quarter Results - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxOd3IwLXdXRnVBT05jZWpNRHpXcE81Z21sN212Ukk2Qng0dmN4bmpKRURDRnZqVTY2NEJpczY1U25ybmtfT3VzcWotdnl5TXBrQy0xclFOWFJBMGRPT01ESnRodVBXTnR6Y1I1NW5oT2xnLXRxTjl0bHVWeEZNTXlkT3RGYkJFWTlGbHZxMl…
VRCA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE4zUEJHUXZUVmVxSnYyMXBGaWZvRUNucUhEN3RqT2JSR0hCQjVEZm9HZWV0LVc1M2JSWDNqZ3Z5YUZPZnMtQURCaTJrUEhnYU9UQmp1OUQ0OTRyMG0tQWNZMG4zNW9jdTZ1elRtZUVWZDdYdms3QjNyeWdn?oc=5" target="_blank">VRC…
VRCA|Verrica Pharmaceuticals Inc|Price:5.520|Chg%:+0.300 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9tdndKdXN1N2JGVWxnNEIwWnc0b3gwYzI4Unh1NDMtU0ZMcjVSazlkR0laWW1RM1hHQUZtS1JxdmxjdkVtYVlNQ2hIUDltZFFYWGZCRkplQlVVMDV6S0ZMVmFfaEFwT2Q4SG9QNlRR?oc=5" target="_blank">VRCA|Verrica Pharma…
Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPdmdfYWdZalZ0NXZjTFdCdmM1UC1FVTJhdDlDVmFUSy00UUpqaWtUZGw1OTdQZzlPTklxVGxHRjdsTXBtVko4RHl0azlQNklUY3VSRnZYNTZwVnFKTjRCNWNLYnFfclZlUS1aX19pRXgyS0p0WG5ocm9kdnF5MFhJMlBsY3FaT3NXWWRRSn…
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - Business Wire
<a href="https://news.google.com/rss/articles/CBMi0gJBVV95cUxOUzdpLXpka1FSc3VnbEp3NWVWU08xcEFxQzRpaHdKbERmd3Jub1JzSWI3OVVzY1lQQWFBYkZxU2dIY1E3NVpiSjhkN2NQU0oxOWZzWTdLZ2V1cGl3ZGlrM1FvVDJOTWZGNXJ0UXpMYXJtNVBHRG9IQ3VzODB1Y2dzZjR4ZjFIem15bHA0RW…
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOZlZ3QUlBVzd5clhFTWdaNTNjMC1fZVNZNDF0YnRyREJOVDZlX0hEMVhoVi1mdWxDWEJHRll6YkxWNVl3X2VndVdQY1h4V0JzOHN6Y3NNUkJUbF9nbFJBdmpZV0VkWE1NQjZydVZGTUpaUVJVQUoxN1llLW5jWFR2ZkMzMzhCMTdsR21mdl…
VRCA — Frequently Asked Questions
What is the current share price of Verrica Pharmaceuticals Inc. (VRCA)?
As of 2026-08-05 17:25 PDT, Verrica Pharmaceuticals Inc. (VRCA) trades at $5.51 on NasdaqCM. Its 52-week range is $3.28 to $9.10.
What is the market capitalisation of VRCA?
Verrica Pharmaceuticals Inc. (VRCA) has a market capitalisation of $94.66M on NasdaqCM.
What is the P/E ratio of VRCA?
VRCA trades at a trailing price-to-earnings (P/E) ratio of -5.01. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is 5.61.
What is the return on equity (ROE) of VRCA?
VRCA has a return on equity (ROE) of -72.29%. Its return on capital employed (ROCE) is -38.90%.
Is VRCA a good stock to buy?
This page provides a data-driven analysis of Verrica Pharmaceuticals Inc. (VRCA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.